QCG
PACB icon

Quadrant Capital Group’s Pacific Biosciences PACB Stock Holding History

Quadrant Capital Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-644
Closed -$851 – 2170
2026
Q1 		$851 Sell
644
-1,910
-75% -$3.42K ﹤0.01% 2600
2025
Q4 		$4.78K Buy
2,554
+1,189
+87% +$2.29K ﹤0.01% 2385
2025
Q3 		$1.75K Sell
1,365
-10,651
-89% -$14.4K ﹤0.01% 2491
2025
Q2 		$14.9K Buy
12,016
+10,344
+619% +$11.9K ﹤0.01% 1335
2025
Q1 		$1.97K Sell
1,672
-1,896
-53% -$2.91K ﹤0.01% 2516
2024
Q4 		$6.53K Buy
3,568
+3,096
+656% +$6.04K ﹤0.01% 2250
2024
Q3 		$803 Sell
472
-139
-23% -$228 ﹤0.01% 2621
2024
Q2 		$838 Buy
611
+82
+16% +$166 ﹤0.01% 2580
2024
Q1 		$1.98K Buy
+529
New +$3.1K ﹤0.01% 2513
2021
Q2 		– Sell
-20
Closed -$1K – 2516
2021
Q1 		$1K Buy
+20
New +$700 ﹤0.01% 2266
2018
Q1 		– Sell
-354
Closed – – 2198
2017
Q4 		$0 Hold
354
– – ﹤0.01% 2147
2017
Q3 		$1K Hold
354
– – ﹤0.01% 2000
2017
Q2 		$0 Buy
+354
New +$1.43K ﹤0.01% 2003

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrant Capital Group's PACB Position: Q2 2026 in Review

Quadrant Capital Group sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 644 shares — an estimated $851 sold.

Quadrant Capital Group first reported a position in PACB in Q2 2017 and held it in 13 quarters. The position peaked at $14.9K in Q2 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Quadrant Capital Group reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 644 Pacific Biosciences shares in Q2 2026, an estimated $851.
  • Quadrant Capital Group first reported a position in Pacific Biosciences in Q2 2017 and held it in 13 quarters.
  • Quadrant Capital Group's Pacific Biosciences position peaked at $14.9K in Q2 2025.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.